The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: A prospective pilot study

Annals of Gastroenterology

Volumn 27, Issue 4, 2014, Pages 387-394

  Mazokopakis, Elias E ^a,b   Papadomanolaki, Maria G ^c   Fousteris, Andreas A ^a   Kotsiris, Dimitrios A ^a   Lampadakis, Ioannis M ^a   Ganotakis, Emmanuel S ^b  

^a Naval Hospital of Crete   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c TECHNICAL UNIVERSITY OF CRETE   (Greece)

Author keywords

Arthrospira; Lipids; Liver; NAFLD; Spirulina; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHROSPIRA PLATENSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BODY HEIGHT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GREECE; HUMAN; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84925247464     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Mazokopakis EE, Starakis IK, Papadomanolaki MG, Mavroeidi NG, Ganotakis ES. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric 2013;94:432-437.
2. Mazokopakis, EE, Karefilakis, CM, Tsartsalis AN, Milkas AN, (Arthrospira platensis). Phytomedicine 2008;15:525-527.
3. Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. Apilot randomized, comparative clinical trial. BMC Gastroenterol 2012;12:32.
4. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications. Evid Based Complement Alternat Med 2011;2011:531053.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
6. Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:1712-1723.
7. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
8. Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009;15:1863-1868.
9. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-180.
10. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-369.
11. Mavrogiannaki AN, Migdalis IN. Non-alcoholic fatty liver disease, diabetes mellitus and cardiovascular disease. Newer data. Hellenic J Atherosclerosis 2013;4:96-103.
12. Söderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;2:595-602.
13. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011;56:3439-3449.
14. WHO (World Health Organization), Obesity: preventing and managing the global epidemic. WHO/NUT/NCD/98.1. Geneva, Switzerland: World Health Organization (1998).
15. International Diabetes Federation (IDF) consensus worldwide definition of the Metabolic Syndrome. International Diabetes Federation 2006. Available on http://www.idf.org/metabolic-syndrome.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. Pediatrics 1988;82:309-318.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-S74.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
20. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
21. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
22. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-583.
23. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:37-54, viii.
24. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009;7:135-140.
25. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver- kidney contrast. Tohoku J Exp Med 1983;139:43-50.
26. Ferreira-Hermosillo A, Torres-Duran PV, Juarez-Oropeza MA. Hepatoprotective effects of Spirulina maxima in patients with non-alcoholic fatty liver disease: a case series. J Med Case Rep 2010;4:103.
27. Deng R, Chow TJ. Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. Cardiovasc Ther 2010;28:e33-e45.
28. Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of Spirulina in type 2 diabetes mellitus patients. Nutr Res Pract 2008;2:295-300.
29. Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY. A randomized double-blind, placebo controlled study to establish the effects of Spirulina in elderly Koreans. Ann Nutr Metab 2008;52:322-328.
30. Kim WY, Kim MH. The change of lipid metabolism and immune function caused by antioxidant material in the hypercholesterolemin elderly women in Korea. Korean J Nutr 2005;38:67-75.
31. Torres-Durán PV, Miranda-Zamora R, Paredes-Carbajal MC, Mascher D, Díaz-Zagoya JC, Juárez-Oropeza MA. Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. Biochem Mol Biol Int 1998;44:787-793.
32. Torres-Durán PV, Miranda-Zamora R, Paredes-Carbajal MC, Mascher D, Blé-Castillo J, Díaz-Zagoya JC, Juárez-Oropeza MA. Studies on the preventive effect of Spirulina maxima on fatty liver development induced by carbon tetrachloride, in the rat. J Ethnopharmacol 1999;64:141-147.
33. Torres-Durán PV, Paredes-Carbajal MC, Mascher D, Zamora-González J, Díaz-Zagoya JC, Juárez-Oropeza MA. Protective effect of Arthrospira maxima on fatty acid composition in fatty liver. Arch Med Res 2006;37:479-483.
34. Blé-Castillo JL, Rodríguez-Hernández A, Miranda-Zamora R, Juárez-Oropeza MA, Díaz-Zagoya JC. Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice. Life Sci 2002;70:2665-2673.
35. Rodríguez-Hernández A, Blé-Castillo JL, Juárez-Oropeza MA, Díaz-Zagoya JC. Spirulina maxima prevents fatty liver formation in CD-1 male and female mice with experimental diabetes. Life Sci 2001;69:1029-1037.
36. Kato T, Takemoto K. Effects of Spirulina on hypercholesterolemia and fatty liver in rats. Japan Nutr Foods Assoc J 1984;37:321.
37. Vadiraja BB, Gaikwad NW, Madyastha KM. Hepatoprotective effect of C-phycocyanin: protection for carbon tetrachloride and R-(+)-pulegone-mediated hepatotoxicty in rats. Biochem Biophys Res Commun 1998;249:428-431.
38. Premkumar K, Abraham SK, Santhiya ST, Ramesh A. Protective effect of Spirulina fusiformis on chemical-induced genotoxicity in mice. Fitoterapia 2004;75:24-31.
39. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010;28:179-185.
40. Weaterbacka J, Lammi K, Hakkinen A. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-2809.
41. Browning J, Davis J, Saboorian M. A low carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology 2006;44:487-488.
42. Assy N, Kaita K, Mymin D, Levy C, Roser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-1934.
43. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-765.
44. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012;57:1773-1781.
45. Nagaoka S, Shimizu K, Kaneko H, et al. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr 2005;135:2425-2430.
46. Han LK, Li DX, Xiang L, et al. Isolation of pancreatic lipase activity-inhibitory component of Spirulina platensis and it reduce postprandial triacylglycerolemia. Yakugaku Zasshi 2006;126:43-49.
47. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007;30:2945-2950.
48. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S25-S28.
49. de Leiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes 1998;106(Suppl 2):10-13.
50. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
51. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129.
52. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
53. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-1066.
54. Hickman I, Jonsson J, Prins J. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419.
55. Petersen K, Dufour S, Befroy D. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608.
56. Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. Afr Health Sci 2013;13:667-672.
57. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999;84:2854-2861.
58. Ballinger AB, Clark ML. L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. Metabolism 1994;43:735-738.
59. Gibbs J, Falasco JD, McHugh PR. Cholecystokinin-decreased food intake in rhesus monkeys. Am J Physiol 1976;230:15-18.
60. Silverstone T, Goodall E. The clinical pharmacology of appetite suppressant drugs. Int J Obes 1984;8(Suppl 1):23-33.
61. Mani UV, Iyer UM, Dhruv SA, Mani IU, Sharma KS. Therapeutic utility of Spirulina. In: Spirulina in human nutrition and health. Edited by ME Gershwin and Amha Belay, CRC Press, Taylor & Francis Group, 2008, 71-99.
62. Mani U, Sadliwala A, Iyer U, Parikh P. The effect of spirulina supplementation on blood haemoglobin levels of anaemic adult girls. J Food Sci Technol 2000;37:642-644.
63. Kurdikeri SM. Effect of spirulina on lipid profile of hyperlipidemics. Thesis, University of Agricultural Sciences, Dharwad, 2006.
64. Kauser F, Parveen S. Effect of spirulina as a nutritional supplement on malnourished children. Indian J Nutr Diet 2001;38:269-272.
65. van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved1H MR spectroscopy. Radiology 2010;256:159-168.
66. Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Curr Opin Clin Nutr Metab Care 2009;12:474-481.